Evidence map›Paper›PMID 38059831›Full record

Observational studyCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2024

Community-Level Factors Associated with Hepatocellular Carcinoma Incidence and Mortality: An Observational Registry Study.

Catherine Mezzacappa, Raiza Rossi, Ariel Jaffe, Tamar H Taddei, Mario Strazzabosco

Open access · hybridAbstract readObservational Study
In one paragraph

Observational study in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Catherine MezzacappaYale Liver Center, Section of Digestive Diseases, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut.ORCID 0000-0001-7181-6902
Raiza RossiYale Liver Center, Section of Digestive Diseases, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut.ORCID 0000-0001-6898-2192
Ariel JaffeYale Liver Center, Section of Digestive Diseases, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut.ORCID 0000-0002-6669-4610
Tamar H TaddeiYale Liver Center, Section of Digestive Diseases, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut.ORCID 0000-0002-6500-1739
Mario StrazzaboscoYale Liver Center, Section of Digestive Diseases, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut.ORCID 0000-0002-1995-6331
Yale Cancer Center · USYale University · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Yale Liver CenterP30DK034989 · NIDDK · YALE UNIVERSITY · PI WAJAHAT Zafar MEHAL · 1986 to 2026
$31.1M
Training Program in Investigative HepatologyT32DK007356 · NIDDK · YALE UNIVERSITY · PI MICHAEL H NATHANSON · 1986 to 2026
$7.4M
NCATS NIH HHS UL1 TR001863NIDDK NIH HHS P30 DK034989NIDDK NIH HHS T32 DK007356
6 · The paper itself

Abstract

backgroundHepatocellular carcinoma (HCC) incidence and outcomes vary across populations in the United States, but few studies evaluate local drivers of observed disparities. We measured HCC incidence at the community level and assessed community-level HCC risk factors with the goal of informing resource allocation to improve early case detection, which is associated with improved outcomes.

methodsClinical and demographic data including census tract of residence for all adults diagnosed with HCC in the Connecticut Tumor Registry between 2008 and 2019 were combined with publicly available U.S. Census and Centers for Disease Control and Prevention (CDC) data at the ZIP Code tabulation area (ZCTA) level. The average annual incidence of HCC was calculated for each ZCTA and associations between community-level characteristics, HCC incidence, stage at diagnosis, and survival were evaluated.

resultsAverage annual HCC incidence during the study period was 8.9/100,000 adults and varied from 0 to 97.7 per 100,000 adults by ZCTA. At the community level, lower rates of high school graduation, higher rates of poverty, and rural community type were associated with higher HCC incidence. Persons with HCC living in the highest incidence ZCTAs were diagnosed at a younger age and were less likely to be alive at 1, 2, and 5 years after diagnosis.

conclusionsCommunity-level socioeconomic factors are strongly associated with HCC incidence and survival in Connecticut. IMPACT: This reproducible geo-localization approach using cancer registry, Census, and CDC data can be used to identify communities most likely to benefit from health system investments to reduce disparities in HCC.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsAdultHumansIncidenceRegistriesSocioeconomic FactorsUnited States

Identifiers

PMID38059831
PMCPMC10872555
OpenAlexW4389434825

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.